Search Videos by Topic or Participant
Browse by Series:

Strategies for Using Iron Chelation Therapy

Panelists: Azra Raza, MD.
Published: Monday, Mar 30, 2015
For High-Definition, Click
If a patient has received over 10 transfusions and has a ferritin level of >1000 it may be necessary to institute iron chelation therapy (ICT), believes Azra Raza, MD. Patients on ICT should be monitored every 2 to 3 months until the ferritin level goes below 500. At that time, ICT can be discontinued, with continued ferritin level monitoring every 2 to 3 months, Raza notes. If ferritin once again surpasses 1000, ICT can be reinstituted.

Raza stresses that the treating hematologist must also be convinced of the need for ICT in chronically transfused patients, and must advise their patients of this therapy. These treatments are necessary, since chronic iron overload can be a serious condition, specifically in patients with myelodysplastic syndromes. To simplify the administration of ICT, the FDA approved an oral formulation of deferasirox as a treatment for patients with chronic iron overload on March 30, 2015. The new formulation is a once-daily tablet.
Slider Left
Slider Right
For High-Definition, Click
If a patient has received over 10 transfusions and has a ferritin level of >1000 it may be necessary to institute iron chelation therapy (ICT), believes Azra Raza, MD. Patients on ICT should be monitored every 2 to 3 months until the ferritin level goes below 500. At that time, ICT can be discontinued, with continued ferritin level monitoring every 2 to 3 months, Raza notes. If ferritin once again surpasses 1000, ICT can be reinstituted.

Raza stresses that the treating hematologist must also be convinced of the need for ICT in chronically transfused patients, and must advise their patients of this therapy. These treatments are necessary, since chronic iron overload can be a serious condition, specifically in patients with myelodysplastic syndromes. To simplify the administration of ICT, the FDA approved an oral formulation of deferasirox as a treatment for patients with chronic iron overload on March 30, 2015. The new formulation is a once-daily tablet.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x